A researcher who studied natural products for cancer at the University of Alabama, Birmingham (UAB), had six papers retracted last month, bringing him to a total of 12.
Four of the recently retracted papers by Santosh Katiyar had appeared in PLOS ONE, and two had been published in Cancer Research. They have together been cited more than 250 times, according to Clarivate Analytics’ Web of Science, and are on subjects including compounds found in grape seeds and green tea.
As we’re fond of repeating, sunlight is the best disinfectant. Which doesn’t jibe with the findings in an eye-catching 2018 paper that found people were less fearful of catching a contagious illness if they were in a dark room or were wearing sunglasses.
Fortunately for us, although not for the researchers, we no longer have to live with the cognitive dissonance. The paper, the journal tells us, will be retracted for flaws in the data — which, thanks to the open sharing of data, quickly came to light.
In a first for the CDC, the agency’s premier scientific publication has retracted a 2016 article on suicide, five months after a news story pointed out serious errors in the paper.
The article, initially published as “Suicide Rates by Occupational Group — 17 States, 2012,” had purported to find that farmers were at particularly high risk of suicide. That result in particular caught the attention of a website called The New Food Economy (TNFE), which last June called out what it said were errors in the CDC’s analysis. And on June 29, the journal, the Morbidity and Mortality Weekly Report (MMWR), issued a reader’s note.
Carlo Croce, a prolific cancer researcher at The Ohio State University in Columbus who was the subject of a front page story in The New York Times last year about allegations of misconduct against him, has had most of a lawsuit he filed against the newspaper thrown out.
As first reported by Courthouse News Service, United States District Judge James Graham tossed all but one of Croce’s claims for defamation against the Times and two of its reporters. That claim — which involved a statement in a letter that reporter James Glanz sent Croce as part of his reporting — survived dismissal, but not on grounds that it inflicted emotional distress, Graham ruled.
The authors of a 2018 paper on the effects of gun laws on domestic violence have retracted the article after discovering errors in their analysis and replaced it with a clean version. The new study shows that some gun laws — particularly ones that keep firearms out of the hands of violent offenders, even if their offenses don’t involve domestic assaults — do seem to reduce the incidence of domestic killings.
The paper, which appeared last November in the American Journal of Epidemiology and received some press coverage, including this piece in the New York Times, looked specifically at whether laws that keep guns away from people convicted of violent crimes beyond domestic abuse reduce the number of intimate partner homicides. It also considered the effect of laws that covered dating partners and not simply spouses or former spouses. The first author is April Zeoli, of Michigan State University. Zeoli has published other papers on the topic and delivered a TEDMED talk on it as well.
Retraction Watch readers may be familiar with the name Piero Anversa. Until several years ago, Anversa, a scientist at Harvard Medical School and the Brigham and Women’s Hospital, was a powerful figure in cardiac stem cell research.
The chief scientific officer of a cannabis product company whose stock price has been hotter than a flaming joint (sorry) was known more than 18 months ago to have committed research misconduct while at the U.S. National Institutes of Health — casting a cloud of suspicion over the firm’s operations.
Marketwatch reported yesterday that the company, India Globalization Capital, which trades on the New York Stock Exchange as IGC, has at least nine other “red flags” for investors, from questions about its ability to manufacture cannabinoids to a history of trouble with the U.S. Securities and Exchange Commission.
Until August, the company’s stock had been trading below 50 cents per share. It began a dramatic rise, eventually reaching $13 per share. MarketWatch notes: